Ocugen Locks In Cash Runway to 2028 as Gene Therapy Platform Heads to Fort Lauderdale and Beyond

Ocugen has closed a $115 million convertible note offering that buys the biotech group more than two years of operating breathing room. The deal, struck in early May, carries a 6.75% coupon and matures in 2034. After retiring existing debt, the company expects to hold roughly $112 million in cash and restricted cash — enough to fund operations into 2028. If remaining warrants held by Janus Henderson are exercised, the total could rise to $127.1 million, adding a further cushion for the capital-intensive late-stage clinical work ahead.

The financing comes at a moment when Ocugen is turning up the volume on its modifier gene therapy platform, a technology that aims to correct imbalances in entire gene networks rather than targeting single mutations. That approach makes it theoretically applicable to multiple retinal diseases — retinitis pigmentosa, Stargardt disease, and geographic atrophy — without needing to engineer a separate therapy for each genetic defect.

Two Major Stops on the May Calendar

The company kicks off its presentation blitz today at the Retina World Congress in Fort Lauderdale, where it will showcase its platform to a global audience of retina specialists. The talk, scheduled for 10:31 to 11:10 a.m. EDT, falls within the session on hereditary and rare retinal diseases moderated by Kourous A. Rezaei and Rishi P. Singh, both prominent figures in the field. The congress draws more than 1,000 physicians and industry representatives from over 50 countries — a crucial forum for a small biotech seeking to build awareness among the clinicians who will ultimately drive patient enrollment and market adoption.

A second platform appearance follows on May 26 at the Stifel 2026 Virtual Ophthalmology Forum, where Ocugen will address investors directly. A webcast of that presentation will remain available on the company’s investor relations website for 30 days. These back-to-back engagements reflect a deliberate strategy to court both the scientific community and the capital markets in parallel. Management has already been making the rounds at other industry gatherings, including meetings in Singapore and the Cell & Gene Meeting on the Mediterranean.

Pipeline Nears Regulatory Thresholds

The clinical centerpiece remains OCU400, Ocugen’s gene therapy candidate for retinitis pigmentosa. The Phase 3 liMeliGhT study has completed enrollment with 140 participants, making it what the company describes as the first and largest registration-directed gene therapy trial for a broad patient population in this indication. The program covers more than 25 genetic mutations.

Should investors sell immediately? Or is it worth buying Ocugen?

Ocugen plans to initiate a rolling Biologics License Application for OCU400 in the third quarter of 2026, with completion targeted for the second quarter of 2027. Parallel to the regulatory work, process validation for manufacturing is expected to stay on track in the current quarter — a critical step, since reproducible production is often the make-or-break factor in commercializing gene therapies.

For OCU410, aimed at geographic atrophy, the company is gearing up to launch a Phase 3 registration study in the third quarter of 2026.

Mixed Signals in the Quarterly Numbers

First-quarter earnings delivered a modest surprise on the top line. Revenue came in at $1.53 million, sharply above the roughly $500,000 analysts had predicted. The net loss per share of $0.06 edged past consensus expectations. While the revenue beat offers a short-term positive, the focus for investors remains squarely on the pipeline’s ability to deliver clinical and regulatory milestones before the cash runway runs out.

The stock closed Wednesday at €1.27, down substantially over the past 30 days but still more than doubled on a year-to-date basis. The current price of around €1.25 sits roughly 21% below its 50-day moving average. The relative strength index of 25 points to technically oversold territory — a setup that may attract bargain hunters if the upcoming conference appearances generate fresh momentum.

With the Stifel forum capping off a month of heightened visibility, the market will be watching closely for any updates on the BLA timeline, enrollment momentum, or manufacturing progress. The next concrete milestone, however, is the start of the OCU400 rolling application in the third quarter — a moment that could define whether Ocugen’s extended runway leads to a clear landing or a longer wait.